LITTLE KNOWN FACTS ABOUT INTERLEUKIN-2 THERAPY.

It's properly comprehended that IL-two is actually a pleiotropic cytokine positioned for the crossroads of T cell activation and regulation. Therefore, it really is vital to engineer an IL-two molecule that is certainly biased in the direction of effector cells bearing the intermediate affinity receptor, for instance naïve and memory CD8+ T cells